Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.
BACKGROUND
Moxifloxacin has a broad antibacterial spectrum and rapid bactericidal activity, and is thus a good option for the treatment of bacterial infections in patients who have undergone organ or bone marrow transplantation. Transplant patients also receive immunosuppressant therapy such as ciclosporin.


OBJECTIVE
The primary objective of this study was to assess the steady-state pharmacokinetics of ciclosporin with and without concomitant treatment with moxifloxacin in transplant recipients. A secondary objective was to determine the safety and tolerability of the combined treatment.


METHODS
Patients (n = 9) with stable graft function after bone marrow or renal transplantation and who were already receiving ciclosporin therapy were enrolled into the study. The patients were given ciclosporin (Sandimmun Optoral) capsules twice daily (total daily dosage 150-380 mg/day) throughout the study period. Moxifloxacin (Avolox) tablets 400 mg once daily were given on days 2-8 inclusive. The primary outcome measure was the change in ciclosporin pharmacokinetics on coadministration with moxifloxacin. Secondary outcomes were the steady-state pharmacokinetics of moxifloxacin and ciclosporin plus its metabolites in patients receiving moxifloxacin and ciclosporin concomitantly. Moxifloxacin pharmacokinetic parameters in the presence of ciclosporin were compared with previously published pharmacokinetic data for moxifloxacin in healthy individuals.


RESULTS
No significant changes occurred in the concentration-time curves of ciclosporin and its metabolites following combination therapy with moxifloxacin. The geometric means of whole blood concentrations of ciclosporin and ciclosporin plus its metabolites on day 1 were similar to those on day 8 following combined administration of ciclosporin and moxifloxacin for 7 days. The ratio of combination treatment to monotherapy for ciclosporin was 1.01 (90% CI 0.91, 1.11) for the area under the blood concentration-time curve from time zero to 12 hours at steady state (AUC(12,ss)) and 0.96 (90% CI 0.88, 1.04) for the maximum steady-state blood drug concentration (C(max,ss)). For ciclosporin plus its metabolites the ratio was 1.07 (90% CI 0.99, 1.17) for AUC(12,ss) and 1.03 (90% CI 0.98, 1.09) for C(max,ss). The pharmacokinetic parameters for moxifloxacin were unaffected by the presence of ciclosporin.


CONCLUSIONS
Concomitant administration of moxifloxacin does not alter the pharmacokinetic parameters of ciclosporin or ciclosporin plus its metabolites in immunosuppressed patients. Therefore, no dose adjustments or additional drug monitoring are required when ciclosporin is coadministered with moxifloxacin.
Stass
Heino
H
Bayer HealthCare AG, Clinical Pharmacology, Wuppertal, Germany. heino.stass@bayerhealthcare.com
Delesen
Heinz
H
Kubitza
Dagmar
D
Mai
Ingrid
I
Bauer
Steffen
S
Roots
Ivar
I
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D001372:Aza Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D024841:Fluoroquinolones; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D007166:Immunosuppressive Agents; D011804:Quinolines; D016572:Cyclosporine; D000077266:Moxifloxacin
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6
8980763
Pharmacol Ther. 1993 Feb-Mar;57(2-3):291-345
8361996
Int J Clin Pharmacol Ther. 2004 Jan;42(1):23-9
14756383
Clin Pharmacokinet. 1988 Feb;14(2):96-121
3282749
Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5
9687407
Clin J Am Soc Nephrol. 2006 Nov;1(6):1263-8
17699357
Expert Rev Anti Infect Ther. 2009 Aug;7(6):645-68
19681692
J Antimicrob Chemother. 1999 Jun;43(6):825-7
10404322
Clin Pharmacokinet. 1997 Feb;32(2):101-19
9068926
Ther Clin Risk Manag. 2006 Dec;2(4):417-34
18360653
J Antimicrob Chemother. 1999 May;43 Suppl B:83-90
10382880
J Chromatogr B Biomed Sci Appl. 1997 Nov 21;702(1-2):163-74
9449568
Infection. 1986;14 Suppl 1:S54-9
3007367
Clin Ther. 2004 Jul;26(7):940-50
15336463
Clin Pharmacol Ther. 1995 Sep;58(3):322-7
7554706
Am J Transplant. 2005 May;5(5):987-94
15816878
J Antimicrob Chemother. 1999 May;43 Suppl B:1-11
10382869
Int J Antimicrob Agents. 2000 Sep;16(1):5-15
11185413
Nephron. 1991;57(2):245-6
2020359
Pharmacotherapy. 2001 Oct;21(10 Pt 2):253S-272S
11642691
Br J Clin Pharmacol. 2007 Dec;64(6):745-9
17555469
Clin Biochem. 1995 Dec;28(6):547-59
8595701
Clin Pharmacokinet. 2001;40 Suppl 1:1-9
11352436
Br J Clin Pharmacol. 1989 Apr;27(4):475-81
2655690
Br J Clin Pharmacol. 2002 Mar;53(3):232-7
11874385
Clin Pharmacol Ther. 1988 Jun;43(6):630-5
3378384
Antimicrob Agents Chemother. 1997 Mar;41(3):709-11
9056020
J Antimicrob Chemother. 1988 May;21(5):679-80
3292498
J Pharm Pharmacol. 2008 Jan;60(1):55-62
18088505
Clin Infect Dis. 2004 Apr 1;38(7):1043-5
15034845